Business Information
The group's principal activity is to develop and commercialize novel biological therapies for patients with cancer. It currently has three product platforms: gvax(R) cancer vaccines, oncolytic virus therapies and cancer gene therapies. The group conducts clinical trials in multiple types of cancer utilizing its gvax(R) cancer vaccines and oncolytic virus therapy product platforms. Gvax vaccines consist of irradiated tumor cells, genetically modified to secrete a hormone that stimulates the body's immune response to vaccines. Oncolytic virus therapies, derived from a common cold virus, are designed to replicate in and kill cancer cells, leaving the normal cells unharmed.
|
|
Name |
Title
|
Email
|
| Stephen Sherwin | Chmn., CEO | N/A | | Joseph Vallner | COO, Pres. | N/A | | Robert Dow | Chief Medical Officer | N/A | | Sharon Tetlow | Sr. VP, CFO | N/A | | Carol Grundfest | Sr. VP - Regulatory Affairs, Portfolio Management | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 1,364 | (82,929) | | 2005 | 4,584 | (64,939) | | 2004 | 11,458 | (97,411)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
